XML 40 R22.htm IDEA: XBRL DOCUMENT v2.3.0.15
Segment and Geographic Information (Tables)
9 Months Ended
Sep. 30, 2011
Segment and Geographic Information [Abstract] 
Information on Segments and a Reconciliation of Consolidated Totals
Information on segments and a reconciliation of consolidated totals are as follows (dollars in thousands):

   
Three months ended
  
Nine months ended
 
   
September 30,
  
September 30,
 
   
2011
  
2010
  
2011
  
2010
 
Revenue:
            
   AHS
            
      Americas
 $281,227  $275,494  $805,946  $792,007 
      EMEA
  73,852   71,505   217,947   219,029 
      APAC
  17,029   11,393   46,725   28,035 
                  
         Subtotal – AHS
  372,108   358,392   1,070,618   1,039,071 
                  
   LifeCell
                
      Americas
  94,507   83,213   278,012   243,375 
      EMEA
  2,934   1,722   8,773   4,318 
                  
         Subtotal – LifeCell
  97,441   84,935   286,785   247,693 
                  
   TSS
                
      Americas
  37,687   41,788   123,206   134,751 
      EMEA
  23,888   21,056   70,949   67,509 
      APAC
  247   537   827   1,261 
                  
         Subtotal – TSS
  61,822   63,381   194,982   203,521 
                  
             Total revenue
 $531,371  $506,708  $1,552,385  $1,490,285 

 
   
Three months ended
  
Nine months ended
  
   
September 30,
  
September 30,
  
   
2011
  
2010
  
2011
  
2010
  
Operating earnings:
             
   AHS
 $154,442  $122,827  $397,631  $340,108  
   LifeCell
  27,511   24,561   80,424   66,432  
   TSS
  (77)  2,506   8,542   5,474 (1)
                   
   Non-allocated costs:
                 
      General headquarter expense (2)
  (15,748)  (12,194)  (42,469)  (35,555 
      Share-based compensation
  (7,859)  (8,739)  (23,738)  (24,173 
      Merger-related expenses (3)
  (5,996)  -   (7,202)  -  
      LifeCell acquisition-related expenses (4)
  (8,856)  (8,809)  (26,567)  (29,437 
                   
         Total non-allocated costs
  (38,459)  (29,742)  (99,976)  (89,165 
                   
             Total operating earnings
 $143,417  $120,152  $386,621  $322,849  
                   
                                   
                 
(1) Includes $7.4 million of expenses associated with the TSS product portfolio rationalization recorded in the second quarter of 2010.
(2) Includes restructuring charges of $2.1 million during the three and nine months ended September 30, 2011 and $5.3 million during the nine months ended September 30, 2010.
(3) Represents expenses related to KCI’s pending merger.
(4) Includes amortization of acquired intangible assets and costs to retain key employees related to our purchase of LifeCell in May 2008.